Cargando…

Moving toward a contemporary classification of drug-induced kidney disease

Drug-induced kidney disease (DIKD) accounts for about one-fourth of all cases of acute kidney injury (AKI) in hospitalized patients, especially in critically ill setting. There is no standard definition or classification system of DIKD. To address this, a phenotype definition of DIKD using expert co...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimzadeh, Iman, Barreto, Erin F., Kellum, John A., Awdishu, Linda, Murray, Patrick T., Ostermann, Marlies, Bihorac, Azra, Mehta, Ravindra L., Goldstein, Stuart L., Kashani, Kianoush B., Kane-Gill, Sandra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633929/
https://www.ncbi.nlm.nih.gov/pubmed/37946280
http://dx.doi.org/10.1186/s13054-023-04720-2
_version_ 1785132718072266752
author Karimzadeh, Iman
Barreto, Erin F.
Kellum, John A.
Awdishu, Linda
Murray, Patrick T.
Ostermann, Marlies
Bihorac, Azra
Mehta, Ravindra L.
Goldstein, Stuart L.
Kashani, Kianoush B.
Kane-Gill, Sandra L.
author_facet Karimzadeh, Iman
Barreto, Erin F.
Kellum, John A.
Awdishu, Linda
Murray, Patrick T.
Ostermann, Marlies
Bihorac, Azra
Mehta, Ravindra L.
Goldstein, Stuart L.
Kashani, Kianoush B.
Kane-Gill, Sandra L.
author_sort Karimzadeh, Iman
collection PubMed
description Drug-induced kidney disease (DIKD) accounts for about one-fourth of all cases of acute kidney injury (AKI) in hospitalized patients, especially in critically ill setting. There is no standard definition or classification system of DIKD. To address this, a phenotype definition of DIKD using expert consensus was introduced in 2015. Recently, a novel framework for DIKD classification was proposed that incorporated functional change and tissue damage biomarkers. Medications were stratified into four categories, including “dysfunction without damage,” “damage without dysfunction,” “both dysfunction and damage,” and “neither dysfunction nor damage” using this novel framework along with predominant mechanism(s) of nephrotoxicity for drugs and drug classes. Here, we briefly describe mechanisms and provide examples of drugs/drug classes related to the categories in the proposed framework. In addition, the possible movement of a patient’s kidney disease between certain categories in specific conditions is considered. Finally, opportunities and barriers to adoption of this framework for DIKD classification in real clinical practice are discussed. This new classification system allows congruencies for DIKD with the proposed categorization of AKI, offering clarity as well as consistency for clinicians and researchers.
format Online
Article
Text
id pubmed-10633929
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106339292023-11-10 Moving toward a contemporary classification of drug-induced kidney disease Karimzadeh, Iman Barreto, Erin F. Kellum, John A. Awdishu, Linda Murray, Patrick T. Ostermann, Marlies Bihorac, Azra Mehta, Ravindra L. Goldstein, Stuart L. Kashani, Kianoush B. Kane-Gill, Sandra L. Crit Care Perspective Drug-induced kidney disease (DIKD) accounts for about one-fourth of all cases of acute kidney injury (AKI) in hospitalized patients, especially in critically ill setting. There is no standard definition or classification system of DIKD. To address this, a phenotype definition of DIKD using expert consensus was introduced in 2015. Recently, a novel framework for DIKD classification was proposed that incorporated functional change and tissue damage biomarkers. Medications were stratified into four categories, including “dysfunction without damage,” “damage without dysfunction,” “both dysfunction and damage,” and “neither dysfunction nor damage” using this novel framework along with predominant mechanism(s) of nephrotoxicity for drugs and drug classes. Here, we briefly describe mechanisms and provide examples of drugs/drug classes related to the categories in the proposed framework. In addition, the possible movement of a patient’s kidney disease between certain categories in specific conditions is considered. Finally, opportunities and barriers to adoption of this framework for DIKD classification in real clinical practice are discussed. This new classification system allows congruencies for DIKD with the proposed categorization of AKI, offering clarity as well as consistency for clinicians and researchers. BioMed Central 2023-11-09 /pmc/articles/PMC10633929/ /pubmed/37946280 http://dx.doi.org/10.1186/s13054-023-04720-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Perspective
Karimzadeh, Iman
Barreto, Erin F.
Kellum, John A.
Awdishu, Linda
Murray, Patrick T.
Ostermann, Marlies
Bihorac, Azra
Mehta, Ravindra L.
Goldstein, Stuart L.
Kashani, Kianoush B.
Kane-Gill, Sandra L.
Moving toward a contemporary classification of drug-induced kidney disease
title Moving toward a contemporary classification of drug-induced kidney disease
title_full Moving toward a contemporary classification of drug-induced kidney disease
title_fullStr Moving toward a contemporary classification of drug-induced kidney disease
title_full_unstemmed Moving toward a contemporary classification of drug-induced kidney disease
title_short Moving toward a contemporary classification of drug-induced kidney disease
title_sort moving toward a contemporary classification of drug-induced kidney disease
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633929/
https://www.ncbi.nlm.nih.gov/pubmed/37946280
http://dx.doi.org/10.1186/s13054-023-04720-2
work_keys_str_mv AT karimzadehiman movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT barretoerinf movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT kellumjohna movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT awdishulinda movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT murraypatrickt movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT ostermannmarlies movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT bihoracazra movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT mehtaravindral movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT goldsteinstuartl movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT kashanikianoushb movingtowardacontemporaryclassificationofdruginducedkidneydisease
AT kanegillsandral movingtowardacontemporaryclassificationofdruginducedkidneydisease